TORONTO, Sept. 14, 2015 /CNW/ - Transition Therapeutics
Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH)
will hold a conference call on Tuesday,
September 15th, 2015 at 4:30 P.M.
EST to discuss full year Fiscal 2015 financial
results. Dr. Tony Cruz,
Chairman and Chief Executive Officer of the Company, will host the
call. Transition will announce its financial results for this
period in a press release to be issued prior to the call. In
order to participate in the conference call, please call (800)
750-5849 (North America) and (416)
981-9035 (International). A webcast is also available at
www.transitiontherapeutics.com A replay of the conference
call will be available on Transition's website for seven days
following the call.
About Transition
Transition is a biopharmaceutical development company, advancing
novel therapeutics for CNS and metabolic disease indications. The
Company's wholly-owned subsidiary, Transition Therapeutics Ireland
Limited is developing CNS drug candidate ELND005 for the treatment
of Alzheimer's disease and Down syndrome. Transition's lead
metabolic drug candidate is TT401 (LY2944876) for the treatment of
type 2 diabetes and accompanying obesity. The Company's shares are
listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock
Exchange under the symbol "TTH". For additional information about
the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases
should be considered accurate only as of the date of the release
and may be superseded by more recent information we have disclosed
in later press releases, filings with the OSC, SEC or otherwise.
Except for historical information, this press release may contain
forward-looking statements, relating to expectations, plans or
prospects for Transition, including conducting clinical trials and
potential efficacy of its products. These statements are based upon
the current expectations and beliefs of Transition's management and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
factors beyond Transition's control and the risk factors and other
cautionary statements discussed in Transition's quarterly and
annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.